General Information:

Id: 11,821 (click here to show other Interactions for entry)
Diseases: COVID-19
Mammalia
review
Reference: Kai H and Kai MInteractions of coronaviruses with ACE2, angiotensin II, and RAS inhibitors-lessons from available evidence and insights into COVID-19 [PMID: 32341442]

Interaction Information:

Comment Several kinds of ARBs (e.g., olmesartan, telmisartan,losartan, and azilsartan) have been shown to increase the mRNA or protein levels of ACE2 in animal models of heart diseases (hypertensive hypertrophy, autoimmune myocarditis, dilated cardiomyopathy, myocardial infarction, and diabetic cardiomyopathy) and chronic kidney disease (hypertensive nephropathy and diabetic nephropathy), as well as normal rat heart and renal vasculature and hypertensive rat aorta (but not the carotid artery). It should be noted that the doses of ARBs and ACEIs used in these animal studies were much greater than those in clinical practice so that the observed effects of these drugs on ACE2 expression and activity could not be extrapolated to clinical situations in humans. Importantly, no clinical data exist regarding the effects of ARBs and ACEIs on human tissue ACE2 expression or activity in vivo.
Formal Description
Interaction-ID: 116771

drug/chemical compound

Angiotensin II type 1 receptor blocker

increases_quantity of

gene/protein

ACE2

Drugbank entries Show/Hide entries for ACE2